Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jan 2;23(1):3-8.
doi: 10.1097/QAD.0b013e32830e6d6d.

Post-step modifications for research on HIV vaccines

Lawrence Corey, M Juliana McElrath, James G Kublin
Review

Post-step modifications for research on HIV vaccines

Lawrence Corey et al. AIDS. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier Plot (% Failure) For Subjects who Received Placebo: MITT* population (males)
See this image and copyright information in PMC

References

    1. Press release from Merck and the HIV Vaccine Trials Network. Whitehouse Station NJ; Seattle, WA: Sept 21, 2007. Vaccination and enrollment are discontinued in phase II trials of Merck’s investigational HIV vaccine candidate. Interim Analysis of STEP Study Shows Vaccine was not Effective.
    1. Cohen J. AIDS research. Promising AIDS vaccine’s failure leaves field reeling. Science. 2007 Oct 5;318(5847):28–29. - PubMed
    1. Mehrotra DV, Li X, Gilbert PB. A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof of concept HIV vaccine trial. Biometrics. 2006;62:893–900. - PubMed
    1. Priddy F, Brown D, Kublin J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type-5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis. 2008;46:1769–1781. - PubMed
    1. Fu TM, Dubey SA, Mehrotra DV, et al. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res Hum Retroviruses. 2007;23(1):67–76. - PubMed